Abstract 19P
Background
SCLC is highly heterogeneous and can be divided into NE (Neuroendocrine)-high and NE-low groups according to 50 genes on transcriptomic level, harboring different immune microenvironments and potential immunotherapy reactivity. However, this is still far from clinical application since the current three classic NE markers (ChrA, Syn,and CD56) are not very satisfactory either for specificity or sensitivity. It is necessary to explore novel NE markers, that are both close to NE gene subtyping and feasible for clinicopathological use.
Methods
Quantitative detection of NE mRNA genes by Nanostring nCounter as well as INSM1 protein by immunohistochemistry was performed simultaneously on 48 whole slides as testing group. Spearman correlation was applied for consistency analysis of 50 genes and INSM1 protein expression, and the best cut-off for INSM1 expression was validated on 247 tissue microarrays for comparison of the 3 traditional NE protein markers for specificity and sensibility as well as prognostic significance.
Results
In 48 cases, quantitative detection revealed 83.3% for NE-high and 16.7% for NE-low, while for INSM1 protein grouping, it was 79.2% (H-score>100) for NE(INSM1)-high and 20.8% (H-score<=100) for NE(INSM1)-low. NE subtypes defined by INSM1 protein and NE genes had significant consistency in terms of proportion (p=0.026). In addition, NE groups also had consistent clinical characteristics and prognostic trend in the two levels. Patients with NE-high and NE(INSM1)-high tended to be in the advanced stage. Patients with NE-high and NE(INSM1)-high subtypes have a tendency to poor prognosis. In 247 cases of validation exploration, INSM1 expression was positively correlated with 3 classical markers, moreover, in triple-negative cases, INSM1 showed a favorable positive rate (1.5%, 3/198). In addition, NE(INSM1)-high patients showed more bronchial invasion and tumor thrombosis than that of NE(INSM1)-low ones (p<0.05), and the OS rates in the NE(INSM1)-high group were slightly lower than those in the NE(INSM1)-low group.
Conclusions
INSM1 has great potential as a marker of NE differentiation and subgrouping, and also shows a certain correlation with prognosis and some clinicopathological factors.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
94P - Harnessing circulating tumor DNA in bronchoalveolar lavage fluid for precise molecular diagnosis of NSCLC
Presenter: Frank Borm
Session: Cocktail & Poster Display session
Resources:
Abstract
95P - Automatic data processing to identify EGFR mutations in pathology reports of patients with non-small cell lung cancer (NSCLC)
Presenter: Betzabel Cajiao Garcia
Session: Cocktail & Poster Display session
Resources:
Abstract
96P - Analysis of concordance between microsatellite instability by next generation sequencing (NGS-MSI) and mismatch repair deficiency by immunohistochemistry (IHC-MMR) in endometrial cancer (EC) patients
Presenter: Simona Duranti
Session: Cocktail & Poster Display session
Resources:
Abstract
97P - Prospects of liquid biopsy in determining prognosis in children with HGG and DIPG
Presenter: Olga Regentova
Session: Cocktail & Poster Display session
Resources:
Abstract
98P - Liquid biopsy in NSCLC: A promising tool to predict immunotherapy response
Presenter: Ana Fernández
Session: Cocktail & Poster Display session
Resources:
Abstract
99P - Comprehensive genomic sequencing as an ancillary diagnostic tool for pathologists
Presenter: Dan Miller
Session: Cocktail & Poster Display session
Resources:
Abstract
100P - Standard serum biomarkers to help predict a cancer diagnosis in patients with non-specific symptoms: Data from Guy´s rapid diagnostic clinic
Presenter: Maria Monroy Iglesias
Session: Cocktail & Poster Display session
Resources:
Abstract
101P - Patient-derived organoids to optimize CDK4/6 inhibitor-based treatment selection in early breast cancer
Presenter: Carla Alves
Session: Cocktail & Poster Display session
Resources:
Abstract
102P - MicroRNAs in urine and saliva as non-invasive biomarkers of minimal residual disease in pediatric acute lymphoblastic leukemia
Presenter: Alejandra Pando-Caciano
Session: Cocktail & Poster Display session
Resources:
Abstract
103P - MSI detection by NGS using tumor samples and liquid biopsy for patients with solid tumors: A single institution experience
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract